| First Author | Carrington EM | Year | 2017 |
| Journal | Cell Death Differ | Volume | 24 |
| Issue | 5 | Pages | 878-888 |
| PubMed ID | 28362427 | Mgi Jnum | J:268909 |
| Mgi Id | MGI:6269757 | Doi | 10.1038/cdd.2017.30 |
| Citation | Carrington EM, et al. (2017) Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death Differ 24(5):878-888 |
| abstractText | Survival of various immune cell populations has been proposed to preferentially rely on a particular anti-apoptotic BCL-2 family member, for example, naive T cells require BCL-2, while regulatory T cells require MCL-1. Here we examined the survival requirements of multiple immune cell subsets in vitro and in vivo, using both genetic and pharmacological approaches. Our findings support a model in which survival is determined by quantitative participation of multiple anti-apoptotic proteins rather than by a single anti-apoptotic protein. This model provides both an insight into how the sum of relative levels of anti-apoptotic proteins BCL-2, MCL-1 and A1 influence survival of T cells, B cells and dendritic cells, and a framework for ascertaining how these different immune cells can be optimally targeted in treatment of immunopathology, transplantation rejection or hematological cancers. |
